Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 146.67 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $103.546 million which beat the analyst consensus estimate of $86.240 million by 20.07 percent. This is a 20.14 percent increase over sales of $86.188 million the same period last year.